FDA Brief

Warning letters Food

FDA warning letter to

CAJ Food Products Inc.

High riskIssued Mar 11, 2022Posted May 31, 2022Office of Human and Animal Food Operations East Division 6

CAJ Food Products marketed Biotta and Juice Performer juices with disease claims, making them unapproved new drugs, FDA says.

What happened

FDA reviewed the company’s Amazon storefronts in November–December 2021 and its linked websites; no inspection is mentioned. It found claims that the juices treat or prevent diseases including cancer, high blood pressure, COPD, diabetes, and gout. FDA said these claims make the products drugs and that they are not FDA-approved for those uses.

What FDA found

  1. Website claims that the juices cure, mitigate, treat, or prevent diseases make them drugs.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The products are new drugs because they are not generally recognized as safe and effective for those uses, and FDA has not approved them.

    sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The products are misbranded because they lack adequate directions for a layperson to use them safely for their intended disease uses.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Selling these misbranded drugs in interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

Within 15 working days of receipt, notify FDA in writing of the specific steps taken to correct the violations and prevent recurrence, with related documents. If corrections will take longer, explain why and give a completion date.

Who should pay attention

  • juice and beverage brands that make health claims
  • retailers and Amazon sellers of juice products
  • companies whose websites describe foods as disease treatments

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk